Featured Research

from universities, journals, and other organizations

Failure rate of antibiotic treatment for gonorrhea documented

Date:
January 8, 2013
Source:
JAMA and Archives Journals
Summary:
In an examination of the effectiveness of cefixime, the only oral cephalosporin antimicrobial recommended for treatment of Neisseria gonorrhoeae (gonorrhea) infections, researchers found a clinical treatment failure rate of nearly 7 percent for patients treated at a clinic in Toronto.

In an examination of the effectiveness of cefixime, the only oral cephalosporin antimicrobial recommended for treatment of Neisseria gonorrhoeae (gonorrhea) infections, researchers found a clinical treatment failure rate of nearly 7 percent for patients treated at a clinic in Toronto, according to a preliminary study published in the January 9 issue of JAMA.

"Because of Neisseria gonorrhoeae resistance to all prior first-line antimicrobial agents, cephalosporin [antibiotic] therapy with adjuvant azithromycin or doxycycline is recommended for treatment of gonorrhea," according to background information in the article. Cefixime is the only oral cephalosporin recommended for gonorrhea treatment. "An increase in the minimum inhibitory concentration [MIC; lowest concentration of an anti-microbial agent that will prevent the growth of an organism] of N gonorrhoeae to cefixime, and to a lesser extent, an intramuscularly administered cephalosporin, ceftriaxone, has been identified in cultured isolates worldwide. The World Health Organization has sounded alarms for the threat of untreatable gonorrhea."

Vanessa G. Allen, M.D., M.P.H., of Public Health Ontario, Toronto, Canada, and colleagues conducted a study to determine whether N gonorrhoeae strains with reduced susceptibilities to cefixime are associated with clinical failures. The study group consisted of N gonorrhoeae culture-positive individuals identified between May 2010 and April 2011 and treated at a sexual health clinic in Toronto with cefixime as recommended by Public Health Agency of Canada guidelines. The primary outcome measure for the study was cefixime treatment failure, defined as the repeat isolation of N gonorrhoeae at the test-of-cure visit identical to the pretreatment isolate by molecular typing and explicit denial of re-exposure.

There were 291 N gonorrhoeae culture-positive individuals identified. Of 133 who returned for test of cure, 13 were culture positive; 9 patients were determined to have experienced cefixime treatment failure, with an overall rate of clinical treatment failure of 6.77 percent. The rate of clinical failure associated with a cefixime MIC of 0.12 μg/mL or greater was 25 percent compared with 1.90 percent of infections with cefixime MICs less than 0.12 μg/mL.

"This study presents the first series of clinical failures of gonorrhea associated with the use of cefixime in North America, identified by the concurrent strategies of routine test-of-cure and culture-based testing for N gonorrhoeae," the authors write.

"In light of the increases in cefixime MICs among isolates of N gonorrhoeae across North America, this study offers preliminary clinical data to support the recent CDC recommendations that cefixime is no longer optimal first-line therapy for the successful treatment of gonorrhea. As elevated MICs to ceftriaxone are also emerging, albeit at 1 to 2 MIC dilutions less than the cefixime MIC, proactive strategies for the identification of clinical failures of N gonorrhoeae to this last commercially available agent are required."

Editorial: Cephalosporin-Resistant Gonorrhea in North America

In an accompanying editorial, Robert D. Kirkcaldy, M.D., M.P.H., of the Division of STD Prevention, Centers for Disease Control and Prevention, Atlanta, and colleagues write that the findings of this study, of documented cephalosporin treatment failures in North America, although expected, "its arrival is deeply troubling; clinicians now face the emergence of cephalosporin-resistant N gonorrhoeae without any well-studied, effective backup treatment options."

"New antibiotics for treating gonococcal infections are needed. A clinical trial sponsored by the National Institute of Allergy and Infectious Diseases examining novel combinations of existing drugs just completed enrollment, and a small study of a new oral agent is ongoing. But the antibiotic pipeline is running dry: continued investment in antibiotic development is critical. Meanwhile, the gonococcus has continued to develop the capability to defeat each new antibiotic used. The threat of drug-resistant gonorrhea is increasing and has reached North America. Clinicians, drug developers, and public health professionals must act now."


Story Source:

The above story is based on materials provided by JAMA and Archives Journals. Note: Materials may be edited for content and length.


Journal Reference:

  1. Vanessa G. Allen et al. Neisseria gonorrhoeae Treatment Failure and Susceptibility to Cefixime in Toronto, Canada. JAMA, January 2013 DOI: 10.1001/jama.2012.176575

Cite This Page:

JAMA and Archives Journals. "Failure rate of antibiotic treatment for gonorrhea documented." ScienceDaily. ScienceDaily, 8 January 2013. <www.sciencedaily.com/releases/2013/01/130108162223.htm>.
JAMA and Archives Journals. (2013, January 8). Failure rate of antibiotic treatment for gonorrhea documented. ScienceDaily. Retrieved July 25, 2014 from www.sciencedaily.com/releases/2013/01/130108162223.htm
JAMA and Archives Journals. "Failure rate of antibiotic treatment for gonorrhea documented." ScienceDaily. www.sciencedaily.com/releases/2013/01/130108162223.htm (accessed July 25, 2014).

Share This




More Health & Medicine News

Friday, July 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Beatings and Addiction: Pakistan Drug 'clinic' Tortures Patients

Beatings and Addiction: Pakistan Drug 'clinic' Tortures Patients

AFP (July 24, 2014) A so-called drugs rehab 'clinic' is closed down in Pakistan after police find scores of ‘patients’ chained up alleging serial abuse. Duration 03:05 Video provided by AFP
Powered by NewsLook.com
Too Few Teens Receiving HPV Vaccination, CDC Says

Too Few Teens Receiving HPV Vaccination, CDC Says

Newsy (July 24, 2014) The Centers for Disease Control and Prevention is blaming doctors for the low number of children being vaccinated for HPV. Video provided by Newsy
Powered by NewsLook.com
New Painkiller Designed To Discourage Abuse: Will It Work?

New Painkiller Designed To Discourage Abuse: Will It Work?

Newsy (July 24, 2014) The FDA approved Targiniq ER on Wednesday, a painkiller designed to keep users from abusing it. Like any new medication, however, it has doubters. Video provided by Newsy
Powered by NewsLook.com
Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Newsy (July 24, 2014) Sheik Umar Khan has treated many of the people infected in the Ebola outbreak, and now he's become one of them. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

    Health News

      Environment News

        Technology News



          Save/Print:
          Share:

          Free Subscriptions


          Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

          Get Social & Mobile


          Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

          Have Feedback?


          Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
          Mobile: iPhone Android Web
          Follow: Facebook Twitter Google+
          Subscribe: RSS Feeds Email Newsletters
          Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins